Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:COEPNASDAQ:DERMNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.64-1.2%$2.01$1.43▼$4.98$164.67M1.49324,925 shs112,343 shsCOEPCoeptis Therapeutics$7.70-38.3%$10.07$2.31▼$13.70$25.91M-0.68116,664 shs714,745 shsDERMJourney Medical$7.47-1.2%$5.94$3.20▼$7.84$172.59M0.981,400 shs84,118 shsTNGXTango Therapeutics$1.46$1.69$1.11▼$12.02$157.84M1.031.08 million shs519,792 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+10.81%-18.00%-39.93%-30.80%COEPCoeptis Therapeutics0.00%-23.00%-17.29%-35.35%+17.74%DERMJourney Medical0.00%+19.52%+26.18%+79.57%+119.71%TNGXTango Therapeutics0.00%+13.18%-9.32%-51.97%-81.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.3772 of 5 stars3.52.00.00.02.50.81.3COEPCoeptis Therapeutics1.1549 of 5 stars0.05.00.00.02.61.70.0DERMJourney Medical2.6856 of 5 stars3.63.00.00.02.81.70.6TNGXTango Therapeutics2.2658 of 5 stars3.50.00.00.03.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00631.71% UpsideCOEPCoeptis Therapeutics 2.00HoldN/AN/ADERMJourney Medical 3.20Buy$9.8832.20% UpsideTNGXTango Therapeutics 3.00Buy$12.33744.75% UpsideCurrent Analyst Ratings BreakdownLatest COEP, TNGX, ACIU, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$27.31M6.03N/AN/A$2.12 per share0.77COEPCoeptis TherapeuticsN/AN/AN/AN/A$0.48 per shareN/ADERMJourney Medical$56.13M3.07$0.26 per share28.37$1.05 per share7.11TNGXTango Therapeutics$42.07M3.75N/AN/A$2.48 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%5/12/2025 (Estimated)COEPCoeptis Therapeutics-$21.27M-$5.80N/A∞N/AN/A-1,094.50%-219.97%N/ADERMJourney Medical-$3.85M-$0.74N/AN/AN/A-31.74%-132.10%-26.90%5/12/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.21N/AN/AN/A-284.42%-49.64%-32.00%5/6/2025 (Estimated)Latest COEP, TNGX, ACIU, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TNGXTango Therapeutics-$0.34N/AN/AN/A$6.73 millionN/A5/12/2025Q1 2025ACIUAC Immune-$0.22N/AN/AN/A$0.32 millionN/A5/12/2025Q1 2025DERMJourney Medical-$0.24N/AN/AN/A$12.05 millionN/A3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million2/27/2025Q4 2024TNGXTango Therapeutics-$0.32-$0.35-$0.03-$0.35$7.84 million$4.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ACOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86COEPCoeptis Therapeutics0.030.400.40DERMJourney Medical1.811.381.03TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%COEPCoeptis Therapeutics13.88%DERMJourney Medical7.25%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%COEPCoeptis Therapeutics24.25%DERMJourney Medical13.16%TNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableCOEPCoeptis Therapeutics23.37 million2.46 millionNot OptionableDERMJourney Medical9023.10 million18.14 millionN/ATNGXTango Therapeutics90108.11 million100.65 millionOptionableCOEP, TNGX, ACIU, and DERM HeadlinesRecent News About These CompaniesBlue Owl Capital Holdings LP Acquires New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 26 at 6:43 AM | marketbeat.comTrv Gp Vi LLC Acquires New Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 22, 2025 | marketbeat.comGilead Sciences Inc. Acquires Shares of 4,854,443 Tango Therapeutics, Inc. (NASDAQ:TNGX)April 20, 2025 | marketbeat.comBrokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33April 19, 2025 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for TNGXApril 18, 2025 | marketbeat.comQ1 EPS Forecast for Tango Therapeutics Reduced by AnalystApril 18, 2025 | americanbankingnews.comQ1 Earnings Forecast for TNGX Issued By HC WainwrightApril 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TNGX Q1 Earnings?April 17, 2025 | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from AnalystsApril 16, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tango Therapeutics (NASDAQ:TNGX)April 16, 2025 | marketbeat.comBarbara Weber, M.D., Elected to ITM Supervisory BoardApril 9, 2025 | markets.businessinsider.comTango Therapeutics cuts nearly one-fifth of staffApril 8, 2025 | biopharmadive.comSchroder Investment Management Group Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 8, 2025 | marketbeat.comShort Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%April 1, 2025 | marketbeat.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at [...]March 25, 2025 | aktiencheck.deTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comBarclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)March 24, 2025 | markets.businessinsider.comTango Therapeutics (TNGX) Receives a Buy from BarclaysMarch 1, 2025 | markets.businessinsider.comTango Therapeutics Advances Cancer Treatment PipelineFebruary 28, 2025 | tipranks.comTango Therapeutics sees cash runway into 3Q26February 27, 2025 | markets.businessinsider.comTango Therapeutics reports Q4 EPS (35c), consensus (34c)February 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOEP, TNGX, ACIU, and DERM Company DescriptionsAC Immune NASDAQ:ACIU$1.64 -0.02 (-1.20%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.67 +0.03 (+1.77%) As of 04/25/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Coeptis Therapeutics NASDAQ:COEP$7.70 -4.77 (-38.25%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.67 -0.03 (-0.40%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Journey Medical NASDAQ:DERM$7.47 -0.09 (-1.19%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.44 -0.03 (-0.40%) As of 04/25/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Tango Therapeutics NASDAQ:TNGX$1.46 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.45 -0.01 (-0.68%) As of 04/25/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
